Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival

Breast Cancer Research and Treatment

Volumn 146, Issue 2, 2014, Pages 411-419

  Wang, Shi Yi ^a,b   Long, Jessica B ^b,c   Hurria, Arti ^d   Owusu, Cynthia ^e   Steingart, Richard M ^f   Gross, Cary P ^b,c   Chen, Jersey ^g  

^a YALE UNIVERSITY   (United States)

^b YALE CANCER CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g KAISER PERMANENTE   (United States)

Author keywords

Breast cancer; Cardiotoxicity; Outcomes research; Survival; Trastuzumab

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CAUSE OF DEATH; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; BREAST NEOPLASMS; CANCER REGISTRY; CARDIOVASCULAR DISEASES; COMORBIDITY; MORTALITY; OUTCOME ASSESSMENT; RISK; RISK FACTOR; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; ODDS RATIO; PATIENT OUTCOME ASSESSMENT; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 84904095651     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3029-0     Document Type: Article

References (39)

1. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707-712 (Pubitemid 19147683)
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182 (Pubitemid 17231334)
3. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat rev Cancer 4(5):361-370 (Pubitemid 38579482)
4. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783-792 (Pubitemid 32222155)
5. Moja L, Tagliabue L, Balduzzi S et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4:CD006243
6. Pivot X, Romieu G, Debled M et al (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14(8):741-748
7. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021-1028
8. Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25(23):3525-3533 (Pubitemid 47310891)
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659-1672 (Pubitemid 41464705)
10. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673-1684 (Pubitemid 41464706)
11. Spielmann M, Roche H, Delozier T et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129-6134
12. Murray LJ, Ramakrishnan S, O'Toole L, Manifold IH, Purohit OP, Coleman RE (2010) Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. Breast 19(5):339-344
13. Webster RM, Abraham J, Palaniappan N, Caley A, Jasani B, Barrett-Lee P (2012) Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? Br J Cancer 106(1):32-38
14. Montserrat M, Leveque D, Barthelemy P, Bergerat JP (2012) Duration of adjuvant trastuzumab treatment in routine practice. Anticancer Res 32(10):4585-4588
15. Piotrowski G, Gawor R, Stasiak A, Gawor Z, Potemski P, Banach M (2012) Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Arch Med Sci 8(2):227-235
16. Tarantini L, Cioffi G, Gori S et al (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18(2):113-119
17. Fried G, Regev T, Moskovitz M (2013) Trastuzumab-related cardiac events in the treatment of early breast cancer. Breast Cancer Res Treat 142(1):1-7
18. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504-2512
19. SEER-Medicare Linked Database http://healthservices.cancer.gov/ seermedicare/overview/. Accessed 20 Sept 2010
20. Carlson RW (2003) NCCN breast cancer clinical practice guidelines in oncology: an update. J Natl Compr Cancer Netw 1(Suppl 1):S61-S63
21. Park HS, Gross CP, Makarov DV, Yu JB (2012) Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. Int J Radiat Oncol Biol Phys 83(5):1365-1373
22. Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167(4):492-499
23. Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8-27 (Pubitemid 128456396)
24. Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130-1139 (Pubitemid 41587600)
25. Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(31):3792-3799
26. Suter TM, Procter M, van Veldhuisen DJ et al (2007) Trastuzumab- associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25(25):3859-3865 (Pubitemid 47477261)
27. Ezaz G, Long JB, Gross GP et al (2014) Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3:e000472
28. Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23):2474-2481 (Pubitemid 44901520)
29. Oliva S, Cioffi G, Frattini S et al (2012) Administration of angiotensin-converting enzyme inhibitors and beta-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? Oncologist 17(7):917-924
30. Curigliano G, Cardinale D, Suter T et al (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann of oncol 23(Suppl 7):155-166
31. Tsai HT, Isaacs C, Fu AZ et al (2014) Risk of cardiovascular adverse events from trastuzumab (Herceptin) in elderly persons with breast cancer: a population-based study. Breast Cancer Res Treat 144(1):163-170
32. Brunello A, Monfardini S, Crivellari D, et al. (2008) Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (>70 years). J Clin Oncol 26 (Abstr 1096). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=55&abstractID=33834. Accessed 7 April 2011
33. Lamont EB, Lan L (2014) Sensitivity of medicare claims data for measuring use of standard multiagent chemotherapy regimens. Med Care 52(3):e15-e20
34. Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL (2014) Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat 145(2):491-501
35. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF (2005) Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 43(5):480-485 (Pubitemid 40694609)
36. Lee DS, Donovan L, Austin PC et al (2005) Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 43(2):182-188 (Pubitemid 40222637)
37. Surveillance, Epidemiology, and End Results Program - Turning Cancer Data Into Discovery. http://seer.cancer.gov/seerstat/databases/ssf/her2-derived. html. Assessed 17 Nov 2013
38. Maggiore RJ, Gross CP, Hurria A (2010) Polypharmacy in older adults with cancer. Oncologist 15(5):507-522
39. Ramjaun A, Nassif MO, Krotneva S et al (2013) Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. J Geriatr Oncol 4(3):271-281